p-Anisic Acid for Health & Longevity
Evidence Review created on 11/14/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: 4-Methoxybenzoic Acid, p-Methoxybenzoic Acid, para-Anisic Acid, Anisic Acid, 4-Anisic Acid, Draconic Acid
Motivation
p-Anisic acid (4-methoxybenzoic acid) is a small plant acid found in anise and related spices, and the body also makes it when it breaks down anethole, the main flavor compound of anise. It is used as a food flavoring and as a plant-derived preservative in skin care, and laboratory work has raised questions about whether it influences blood sugar control, skin pigment and inflammation.
Interest has come from several directions. Researchers studying a memory drug found that the body turns it partly into p-anisic acid, cosmetic chemists adopted the acid as an alternative to conventional preservatives, and a recent animal study examined it in a model of type 2 diabetes. It is not sold as a mainstream dietary supplement, so most people meet it through food, fragrance and skin care rather than as a deliberate intake.
This review examines p-anisic acid as an intentional intervention for health-focused adults: the human and laboratory evidence behind each proposed benefit, its known and unknown risks, how the body handles it, and which open questions decide whether it has any place in a longevity program.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists the academic articles that discuss p-anisic acid’s biology, uses and research status in the most depth.
-
Tyrosinase inhibition kinetics of anisic acid - Kubo et al., 2003
Characterizes p-anisic acid from anise as a reversible inhibitor of tyrosinase (the enzyme that starts melanin pigment production), which underlies its skin-care interest.
-
Anti-Diabetic and Insulinotropic Effects of p-Anisic Acid in High-Fat Diet and Streptozotocin Induced Type-2 Diabetic Rats - Vora et al., 2024
An animal test of purified p-anisic acid on blood sugar control, comparing three doses with a standard diabetes drug over four weeks; useful for judging how early the metabolic case is.
-
Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries - Nakamura, 2002
Reviews, from aniracetam’s developer Nippon Roche, how the memory drug aniracetam yields p-anisic acid as a metabolite and the rodent work showing p-anisic acid itself alters acetylcholine and dopamine release in the brain.
-
Bioactive (Co)oligoesters as Potential Delivery Systems of p-Anisic Acid for Cosmetic Purposes - Martinka Maksymiak et al., 2020
Summarizes reported p-anisic acid bioactivities and tests slow-release carriers on human keratinocytes (skin surface cells), showing how formulation research approaches topical use.
Only four items are listed: no other article, blog, podcast or video discusses p-anisic acid in substantial depth.
No content on p-anisic acid was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; the compound is not marketed as a longevity supplement, and none of these outlets has covered it.
Grokipedia
Covers chemical identity, synonyms such as draconic acid, physical properties, natural sources such as anise, and its uses as a preservative and synthesis intermediate; health content is minimal.
Examine
No Examine article on p-anisic acid exists.
ConsumerLab
No ConsumerLab article on p-anisic acid exists.
Systematic Reviews
This section lists the only systematic review on PubMed that evaluates p-anisic acid.
-
A review and in silico screening of plant-derived snake venom/toxin inhibitors: ADMET, drug-likeness, and medicinal chemistry profiling - Ojuka et al., 2025
Ranks anisic acid among the strongest plant-derived antivenom candidates from animal and laboratory data; it addresses venom neutralization, not health or longevity outcomes.
No systematic review or meta-analysis covers any health or longevity benefit of p-anisic acid, nor its risks; both the claimed effects and the principal risks are unrepresented.
Mechanism of Action
p-Anisic acid is benzoic acid carrying a methoxy group (an oxygen-linked methyl group) opposite its acid group. Its proposed actions come from laboratory and animal work:
- Tyrosinase inhibition: it reversibly slows tyrosinase, the enzyme that starts melanin pigment production, with an IC50 (the concentration that halves enzyme activity) of 0.60 mM (millimolar) (Kubo 2003).
- Phospholipase A2 binding: it binds and inhibits phospholipase A2 (PLA2, an enzyme that triggers inflammatory signaling) (Singh 2006).
- Insulin secretion: a phospholipid conjugate of p-anisic acid, not the free acid, increased glucose-triggered insulin secretion in mouse pancreatic cells via GPR40, GPR55 and GPR119 (fat-sensing receptors) (Drzazga 2020).
- Brain signaling: perfused into rat brain, it increased release of acetylcholine, a memory-related signaling chemical, in work from aniracetam’s developer, Nippon Roche (Nakamura 1999).
A competing finding: in human fibroblasts (connective-tissue cells), 4-methoxybenzoic acid did not activate the proteasome (the cell’s protein-recycling machinery), whereas related benzoic acids did (Georgousaki 2020).
Pharmacology: In human volunteers, anethole was excreted mainly as 4-methoxyhippuric acid, the glycine conjugate of p-anisic acid (Caldwell 1988), formed by glycine N-acyltransferase (GLYAT, a glycine-attaching enzyme). After oral aniracetam, serum anisic acid peaked at 2 hours and returned to baseline by 6 hours (Endo 1997); half-life was 4- to 7-fold longer in very old, kidney-impaired patients than in young volunteers (Endo 1997). A review reports rat brain p-anisic acid exposure at about 4% of blood levels after intravenous aniracetam (Nakamura 2002). No cytochrome P450 (liver drug-metabolizing enzyme) pathway has been characterized; target selectivity is low.
Historical Context & Evolution
p-Anisic acid was first obtained in the 19th century by oxidizing anethole from anise oil, and its original uses were as a chemical intermediate and a flavoring. The Joint FAO/WHO (Food and Agriculture Organization / World Health Organization) Expert Committee on Food Additives (JECFA) lists it as a flavouring agent under the name 4-methoxybenzoic acid, with draconic acid among its synonyms (JECFA evaluation). It was never developed as a medicine.
Interest in health effects arrived indirectly, through several separate lines of research:
- Food metabolism: a volunteer study traced the anise flavoring anethole to 4-methoxybenzoic acid and its glycine conjugate in urine (Caldwell 1988).
- Memory-drug research: researchers found that p-anisic acid, a metabolite of the memory drug aniracetam, raised acetylcholine release in rat brain while aniracetam itself did not (Nakamura 1999).
- Venom and inflammation: anisic acid neutralized lethal snake-venom effects in animals (Alam 1998), and later crystal-structure work showed it binding the venom enzyme PLA2 (Singh 2006).
- Cosmetics: it was characterized as a tyrosinase inhibitor from anise seed (Kubo 2003) and adopted as an antimicrobial ingredient in self-preserving formulas (Papageorgiou 2010).
- Metabolic disease: a 2024 rat study reported antidiabetic effects (Vora 2024).
None of these lines has reached a human efficacy trial, so no finding has yet been confirmed or refuted in people. Current interest reflects accumulating laboratory signals rather than a settled clinical judgment in either direction.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no randomized or controlled human trial has tested p-anisic acid on any clinical endpoint or validated surrogate marker.
Medium 🟩 🟩
No benefit reaches Medium: there is no single human trial and no comparison-group observational study linking p-anisic acid intake to any health outcome.
Low 🟩
No benefit reaches Low: the only human data are pharmacokinetic studies (how the body absorbs and clears a compound), which measured no health outcome.
Speculative 🟨
Blood Sugar and Insulin Support
In type 2 diabetic rats, four weeks of p-anisic acid lowered blood glucose and improved HbA1c (glycated hemoglobin, a three-month blood sugar average), insulin and blood lipids (Vora 2024). The basis is animal data only.
Anti-Inflammatory Enzyme Inhibition
p-Anisic acid binds and inhibits PLA2, the enzyme that releases the raw material for inflammatory signaling molecules (Singh 2006). The basis is crystal-structure and enzyme data; no human inflammation marker was measured.
Cholinergic (Acetylcholine-Signaling) and Anxiety-Related Brain Effects
Infused into rat brain, p-anisic acid raised acetylcholine release (Nakamura 1999), and it mimicked aniracetam’s anti-anxiety effect in a mouse maze test (Nakamura 2001). The basis is rodent data only.
Skin Pigment Regulation ⭕️ Not Central to Health & Longevity
p-Anisic acid reversibly inhibits tyrosinase, the enzyme that starts melanin pigment production, in enzyme assays (Kubo 2003). No skin study exists. It bears on cosmetic pigmentation, not on health or lifespan.
Antimicrobial Preservation of Topical Products ⭕️ Not Central to Health & Longevity
In laboratory challenge tests (deliberate microbial contamination), adding 0.1% w/w (weight per weight) p-anisic acid to a combined self-preserving system met the strictest microbial criterion (Papageorgiou 2010). It bears on product stability, not user health.
Snake Venom Neutralization ⭕️ Not Central to Health & Longevity
In animals and laboratory tests, anisic acid neutralized the lethal and clot-depleting effects of four Indian snake venoms (Alam 1998). It bears on snakebite treatment, not longevity. The basis is animal data only.
Benefit-Modifying Factors
- Genetic variation: No study links any gene variant to p-anisic acid response; variants in glycine N-acyltransferase (GLYAT, the enzyme that attaches glycine to acids for urinary excretion) could, in theory, change how long free acid circulates.
- Baseline blood sugar: The only metabolic data come from diabetic rats (Vora 2024); any glucose effect in people would plausibly be largest with elevated fasting glucose or HbA1c and smallest with normal values.
- Sex: Not studied; the diabetic rat study used males only (Vora 2024).
- Pre-existing conditions: Type 2 diabetes is the only condition modeled; no data exist for metabolically healthy adults, the typical longevity-focused user.
- Age: No age-specific benefit data exist; slower clearance in very old patients with reduced kidney function (Endo 1997) would lengthen exposure from any given amount.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no controlled human trial of p-anisic acid has recorded adverse events.
Medium 🟥 🟥
No risk reaches Medium: no single human trial or comparison-group observational study has measured harms of p-anisic acid intake.
Low 🟥
Slower Clearance With Reduced Kidney Function
After a 200 mg aniracetam dose, elderly women with poor kidney function cleared the anisic acid metabolites far more slowly than young volunteers (Endo 1997). No side effects were observed. The evidence is indirect: exposure came from aniracetam, not p-anisic acid itself.
Magnitude: Half-life of anisic acid and p-methoxyhippuric acid 4- to 7-fold longer than in young volunteers, at a mean creatinine clearance (a kidney filtering measure) of 20–30 mL/min (Endo 1997); no side effects were observed in the six patients (Endo 1997), and no adverse-event rate is reported for the comparison group.
Speculative 🟨
Additive Blood Sugar Lowering
Because p-anisic acid lowered blood glucose in diabetic rats (Vora 2024), it could add to glucose-lowering drugs and cause hypoglycemia (abnormally low blood sugar). The basis is animal data only.
Uneven Skin Lightening With Topical Use
Tyrosinase inhibition (Kubo 2003) could, in theory, lighten skin where concentrated products are applied. No human report exists; the basis is enzyme-assay data only.
Altered Brain Signaling
A review reports that p-anisic acid infused into rat prefrontal cortex (the brain’s front planning region) enhanced dopamine release (Nakamura 2002). Human effects are unknown; the basis is rodent-only.
Risk-Modifying Factors
- Genetic variation: No study has examined GLYAT variants or UGT enzymes (UDP-glucuronosyltransferases, which attach glucuronic acid to compounds for excretion); slow-conjugating variants could, in theory, prolong exposure.
- Baseline kidney function: Elderly patients with creatinine clearance of 20–30 mL/min cleared aniracetam-derived anisic acid more slowly than young volunteers (Endo 1997); age and kidney function were not separated; serum creatinine and eGFR (estimated glomerular filtration rate, a calculated kidney filtering measure) identify this group.
- Sex: No sex comparison exists; the only human clearance study in older patients enrolled women only (Endo 1997).
- Pre-existing conditions: Diabetes treated with insulin or sulfonylureas (oral drugs that force insulin release) raises the theoretical hypoglycemia concern; vitiligo (patchy loss of skin color) and other pigment disorders raise the theoretical topical lightening concern.
- Age: Patients in their 80s cleared anisic acid metabolites 4 to 7 times more slowly than young volunteers (Endo 1997), consistent with age-related kidney decline.
Key Interactions & Contraindications
Documented interactions:
- Aniracetam (a memory drug): Aniracetam is metabolized to anisic acid in people (Endo 1997), so combining the two adds to the same exposure, which persists longer with poor kidney function. Counting both sources toward total intake limits accumulation.
- Anethole-rich foods and oils (anise, star anise, fennel): Anethole is converted to 4-methoxybenzoic acid and its glycine conjugate in people (Caldwell 1988), adding background exposure that could raise accumulation with poor kidney function; concentrated anise oils add more than culinary amounts.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Glucose-lowering drugs (insulin, glipizide, glimepiride, metformin): Additive glucose lowering, inferred from rat data, could cause hypoglycemia. More frequent glucose checks during the first weeks address this.
- Glucose-lowering supplements (berberine, cinnamon extract, chromium): Additive glucose lowering, inferred from the same rat data, could cause hypoglycemia, especially when combined with drugs. Glucose checks during the first weeks address this.
- Salicylates and benzoates (aspirin-family drugs and benzoic acid preservatives: aspirin, salsalate, sodium benzoate): These share glycine conjugation, the pathway that clears p-anisic acid as 4-methoxyhippuric acid; high combined doses could slow clearance of either acid. Separating high doses by several hours reduces overlap.
- Topical tyrosinase inhibitors (hydroquinone, kojic acid, arbutin): Additive inhibition of melanin production could cause uneven lightening at the application site. A small-area trial application precedes broad use.
- Prolonged fasting or very-low-carbohydrate diets: Additive glucose lowering, inferred from the rat data, could cause hypoglycemia; glucose checks on fasting days address this.
Populations who should avoid p-Anisic Acid:
- Pregnancy and breastfeeding: Inferred from the absence of any reproductive or lactation data for a compound with enzyme and brain-signaling activity; no human data.
- Severely reduced kidney function (creatinine clearance 20–30 mL/min or lower): Inferred from 4- to 7-fold slower clearance at that level (Endo 1997); no human harm data.
- Insulin- or sulfonylurea-treated diabetes with past hypoglycemia: Inferred from glucose lowering in rats; no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Kidney check before use: Measuring serum creatinine and eGFR before oral use identifies reduced clearance; exposure is avoided at creatinine clearance of 20–30 mL/min or lower, the range with 4- to 7-fold slower clearance (Endo 1997).
- Glucose checks with diabetes drugs: Home checks once or twice daily for 2 weeks detect hypoglycemia; readings below 70 mg/dL, the American Diabetes Association (ADA) threshold (ADA Standards 2025, Section 6), prompt stopping; its members earn from diabetes care.
- Small-area skin test: Applying a topical product to a 2 × 2 cm area for 48 hours before wider use detects irritation and limits uneven lightening.
- No combining with aniracetam: Avoiding simultaneous aniracetam use prevents cumulative anisic acid exposure, which matters most with reduced kidney function.
- Lowest exposure first: Keeping intake near food-flavoring levels limits additive blood sugar lowering and accumulation with slower kidney clearance, the risks identified above.
Therapeutic Protocol
No oral dose of p-anisic acid has been tested in humans; timing, splitting and titration below reflect common practice unless cited.
- Standard protocol: No practitioner, clinic or guideline has published a p-anisic acid protocol, and no expert has popularized it; it is not an established supplement.
- Dietary exposure: A human metabolism study of anethole used 1 mg as close to daily dietary intake and 50 mg as the amount in a normal measure of anise-flavored beverage (Caldwell 1988).
- Topical approach: Infant cosmetics contained 0.042–0.16% p-anisic acid (Chen 2024); a self-preserving system used 0.1% w/w (Papageorgiou 2010).
- Experimental oral doses: Diabetic rats received 25, 50 or 100 mg/kg for four weeks (Vora 2024); no human-equivalent dose has been validated.
- Indirect exposure via aniracetam: A review of aniracetam trials reports 1,500 mg/day aniracetam (Lee 1994), a drug regimen that yields anisic acid as a metabolite, not a p-anisic acid dose.
- Competing approaches: Topical use (preservation, pigment) and oral use (metabolic, brain) are separate approaches with separate laboratory evidence; neither is established as the default.
- Time of day: No data exist; taking any oral amount with a meal is common practice where glucose lowering is a concern.
- Half-life: After aniracetam in elderly patients, serum anisic acid peaked at 2 hours and returned to baseline by 6 hours (Endo 1997); clearance slows with poor kidney function.
- Single vs. split dosing: Untested; the short persistence implies split doses would be needed to sustain blood levels.
- Genetic factors: No pharmacogenetic data exist; GLYAT and UGT variants could, in theory, alter exposure.
- Sex differences: No sex-specific dosing or response data exist.
- Age: Hospitalized patients in their 80s with reduced kidney function cleared anisic acid metabolites more slowly (Endo 1997); lower exposure is the conventional precaution.
- Baseline biomarkers: Fasting glucose, HbA1c and kidney function at baseline frame any expected glucose effect and clearance.
- Pre-existing conditions: Kidney impairment and drug-treated diabetes change the risk side of any protocol more than the benefit side.
Discontinuation & Cycling
- Duration: No duration is defined; the longest exposure studied is four weeks in rats (Vora 2024), while dietary exposure from anise-flavored foods is lifelong and low.
- Withdrawal effects: None reported; no study has examined stopping.
- Tapering: Not applicable; no dependence or rebound mechanism is known.
- Cycling: Not studied; no tolerance mechanism has been described, so cycling has no evidence-based rationale.
Sourcing and Quality
- Isomer identity: The para (4-) isomer carries CAS (Chemical Abstracts Service) number 100-09-4; ortho- and meta-anisic acids are different compounds with different properties.
- Grade and purity: Food-grade material corresponds to the flavouring evaluated as JECFA No. 883 (JECFA evaluation); a certificate of analysis covering purity, heavy metals and residual solvents is the basic quality document.
- Third-party testing: No supplement-grade product carries third-party certification (USP, the United States Pharmacopeia; NSF International); independent laboratory testing is the only external check.
- Suppliers: Chemical suppliers such as Sigma-Aldrich (Merck) sell food-grade p-anisic acid; cosmetic blends such as Dermosoft 1388 (Evonik) supply sodium anisate, its salt, for formulation.
- Natural sources: Anise, star anise and fennel provide anethole, which the body converts to p-anisic acid (Caldwell 1988); amounts are small and uncontrolled.
Practical Considerations
- Time to effect: Unknown in humans; rat glucose effects were assessed after four weeks of dosing (Vora 2024).
- Common pitfalls: A chemical supplier’s article, from a seller of the compound (ChemicalBook article) describes widespread clinical anti-bleeding use, citing only a venom study (Uma 2000); no human trial supports this. Confusing anise oil, anethole and p-anisic acid is also common.
- Regulatory status: JECFA found “No safety concern at current levels of intake when used as a flavouring agent” (JECFA evaluation); no evaluation covers supplemental doses.
- Cost and access: Inexpensive as a chemical, but not sold as a labeled dietary supplement; access runs through chemical or cosmetic-ingredient suppliers.
Interaction with Foundational Habits
- Sleep: None known: no study has measured sleep. Rodent acetylcholine (Nakamura 1999) and dopamine (a review, Nakamura 2002) effects give no clear direction, so evening intake effects are unknown.
- Nutrition: Indirect: anise, star anise and fennel supply anethole that the body converts to p-anisic acid and clears with glycine (Caldwell 1988). Potentiating, in theory, with carbohydrate restriction, given rat glucose lowering (Vora 2024).
- Exercise: None known: no study has examined exercise performance, recovery or training adaptation, and no mechanism suggests blunting.
- Stress management: Indirect and possibly potentiating: p-anisic acid mimicked aniracetam’s anti-anxiety effect in a mouse maze test (Nakamura 2001); no human stress, mood or cortisol data exist.
Monitoring Protocol & Defining Success
Baseline: Before any intentional oral use, baseline testing documents kidney function and blood sugar status, because slower clearance with poor kidney function and possible glucose lowering are the two plausible concerns. Fasting glucose, HbA1c and serum creatinine with eGFR form the core panel, drawn in the morning after an overnight fast.
Ongoing: Repeat fasting glucose at 2 and 4 weeks, then HbA1c and serum creatinine every 3 months while use continues. People taking glucose-lowering drugs add home glucose checks once or twice daily during the first 2 weeks. Success is defined by a stable or improved glucose profile without a rise in creatinine; no other measurable benefit has been established.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Fasting plasma glucose | Below 100 mg/dL (ADA diagnostic cutoff for normal fasting glucose) | Expected to change: rat data suggest lowering; also a hypoglycemia safety check | 8-hour fast, morning draw; 100–125 mg/dL defines prediabetes (ADA Standards 2025, Section 2); ADA members earn from diabetes care |
| HbA1c | Below 5.7% (ADA diagnostic cutoff below prediabetes) | Expected to change: reflects any sustained glucose effect | No fast needed; reflects about 3 months; 5.7–6.4% defines prediabetes (ADA Standards 2025, Section 2); ADA members earn from diabetes care |
| Serum creatinine | Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL (standard reference range) | Safety check: rising values signal slower clearance | Used to calculate eGFR; avoid intense exercise and large meat meals for 24 hours before the draw |
Qualitative markers:
- Skin tone at topical application sites (uneven lightening)
- Shakiness, sweating or confusion between meals (possible low blood sugar)
- Mood, anxiety level and mental alertness
- Digestive comfort after oral intake
Emerging Research
- Registered trials: A ClinicalTrials.gov search in November 2026 found no registered trial, ongoing or completed, of p-anisic acid or sodium anisate; no NCT ID (ClinicalTrials.gov registration number) exists, so no trial result is expected to change the conclusion soon.
- Metabolic replication: The antidiabetic signal rests on one rat study (Vora 2024); replication by independent groups and a human glucose study would strengthen the case, while null replication would remove its main health rationale.
- Conjugate designs: A phospholipid conjugate of p-anisic acid stimulated insulin secretion in pancreatic cells (Drzazga 2020), pointing research toward modified derivatives rather than the free acid.
- Aging biology: In human fibroblasts, 4-methoxybenzoic acid failed to activate the proteasome, whereas related benzoic acids did (Georgousaki 2020), weakening the case for the free acid as a protein-recycling modulator.
- Human pharmacokinetics: No study has dosed pure p-anisic acid orally in people; current human data come from aniracetam (Endo 1997) and anethole (Caldwell 1988), leaving dose-exposure relationships unknown.
- Long-term safety: No chronic oral safety study in humans exists; such data could either clear supplemental use or reveal problems that food-level exposure never shows.
Conclusion
p-Anisic acid is a simple plant acid that people already take in at small amounts from anise-flavored foods and that their bodies also make from anise’s main flavor compound. It is used mainly as a flavoring and as a preservative in skin care, not as a health supplement.
For health-focused adults weighing it as a deliberate intake, every proposed benefit rests on laboratory or animal work: better blood sugar control in diabetic rats, blocking of an enzyme that drives inflammation, effects on brain chemicals tied to memory and anxiety in rodents, and slowing of the enzyme that makes skin pigment. None has been tested in people, and one cell study found no effect on the protein-recycling system linked to aging.
The risk picture is thin. An international food-safety committee found no safety concern at flavoring levels, but deliberate higher intake has never been studied. The clearest human signal is that people with reduced kidney function and very old adults clear the compound much more slowly. Possible blood sugar lowering alongside diabetes treatment and uneven skin lightening from concentrated products remain theoretical.
The evidence base is small; the rodent brain work comes from a memory-drug maker; a supplier’s web page selling the compound claims unsupported anti-bleeding use, and the blood sugar thresholds come from a diabetes association whose members earn from diabetes care. Overall, p-anisic acid is a biologically active compound with no demonstrated human health or longevity benefit, and its value as a deliberate intervention remains unknown.